Corgenix Medical Corporation, a worldwide developer and marketer of diagnostic test kits, has signed an exclusive agreement with the Medison Group to market its AspirinWorks test kits in Israel. This will allow individuals with risk of heart attack to rapidly determine if aspirin therapy is effective for them.
The AspirinWorks® Test Kit is an enzyme-linked immunoassay (ELISA) to determine levels of 11-Dehydro Thromboxane B2 (11dhTxB2) in human urine, which aids in the qualitative detection of aspirin effect in apparently healthy individuals post ingestion.
Its strong advantage is its ease of application. Unlike other platelet aggregation tests, which require freshly drawn blood that must be evaluated within 4 hours, AspirinWorks is non-invasive and requires only a urine sample that can easily be obtained in any doctor’s office. It is not time-sensitive.
“Research has shown that up to 25 percent of individuals may be non-responsive to aspirin’s benefits, and are more than three times more likely to die from heart disease,” said Corgenix Clinical Affairs Director Gordon Ens. “This test can tell us if the aspirin fails to elicit an effect, thereby allowing physicians to individualize their patient’s therapy.”
The AspirinWorks® diagnostic test kit targets a potential U.S. market of over 60 million individuals and a potential global market exceeding 200 million individuals.
More than one million Americans experience new or recurrent heart attacks each year.
Corgenix Medical Corporation
Corgenix Medical Corporation (OTC BB: CONX) is a leader in the development and manufacturing of specialized diagnostic kits for immunology disorders, vascular diseases and bone and joint disorders. Corgenix diagnostic products are commercialized for use in clinical laboratories throughout the world. The company currently sells over 50 diagnostic products through a global distribution network and has significant experience in advancing products through the FDA process.
For more information: www.corgenix.com.
Medison Pharma
Medison Pharma is a leading Israeli marketing group focused in the fields of high quality pharmaceutical, medical devices and diagnostics products. With over a decade of experience, Medison is uniquely placed to provide a complete A to Z spectrum of integrated services for international companies looking to enter or expand their presence in the Israeli healthcare market, as well as in Romania and Slovakia.
Contact: Medison Pharma Ltd, Israel Tel: + 972-3-9250250 Email: medison@medison.co.il Site: www.medisonpharma.com
